

# **Principles of Immunopharmacology**

Edited by Frans P. Nijkamp  
and Michael J. Parnham

# Contents

Preface to the first edition . . . . .	xv
Preface to the second edition . . . . .	xvi
Abbreviations . . . . .	xvii
<b>A Mechanisms of immunity</b>	
<b>A.1 Hematopoiesis, including lymphocyte development and maturation</b>	
Introduction: acquisition of specificity. . . . .	3
Hematopoiesis. . . . .	3
T and B lymphocytes: common origin from hematopoietic stem cells. . . . .	6
Specificity: rearrangement of genes encoding antigen receptors. . . . .	7
T lymphocyte maturation in the thymus. . . . .	8
B lymphocyte development in the bone marrow. . . . .	11
Mature T and B lymphocytes: tolerance. . . . .	14
T and B lymphocyte development and maturation: relevance for immunopharmacology. . . . .	14
Summary. . . . .	15
Selected readings. . . . .	16
Recommended Website. . . . .	16
References. . . . .	16
<b>A.2 T cell-mediated immunity</b>	
Introduction. . . . .	19
Biology of the T lymphocyte immune response. . . . .	19
Composition of the T cell network. . . . .	20
T cell subset markers. . . . .	22
Effectors of T cell-mediated immunity. . . . .	23
Mechanisms of T cell-mediated cytotoxicity. . . . .	24
Mechanisms of T cell activation. . . . .	25
Tolerance. . . . .	26
Summary. . . . .	28
Selected readings. . . . .	28
<b>A.3 Antibody diversity and ES cell-mediated immunity</b>	
Antibodies and immunoglobulins. . . . .	29
Structure of immunoglobulins. . . . .	29
The generation of antibody diversity. . . . .	30
B cell receptor and Signal transduction . . . . .	32
B lymphocyte costimulation. . . . .	34

Cytokine regulation . . . . .	36
T cell-independent B lymphocyte activation . . . . .	36
Primary and secondary antibody response . . . . .	37
Biological functions of antibodies . . . . .	39
Clinical relevance and future prospects . . . . .	41
Summary . . . . .	43
Selected readings . . . . .	43
Recommended Websites . . . . .	43
References . . . . .	44
<b>A.4 Cytokines</b>	
Introduction . . . . .	45
Differentiation factors . . . . .	46
Activation and growth factors of lymphocytes . . . . .	48
Mediators of inflammation . . . . .	51
Regulatory factors of immune reactions . . . . .	54
Chemokines . . . . .	54
Inhibition of cytokines . . . . .	58
Summary and outlook . . . . .	60
Selected readings . . . . .	60
Recommended website . . . . .	60
References . . . . .	60
<b>A.5 Innate immunity - phagocytes, natural killer cells and the complement System</b>	
Phagocytes . . . . .	53
Natural killer cells . . . . .	72
The complement System . . . . .	75
Summary . . . . .	79
Selected readings . . . . .	79
References . . . . .	79
<b>A.6 Inflammatory mediators and intracellular signalling</b>	
Introduction . . . . .	81
Eicosanoids . . . . .	81
Platelet-activating factor (PAF) . . . . .	87
Toll-like receptors . . . . .	89
Cytokines . . . . .	89
Chemokines and their [ntracellular signalling . . . . .	92
Neuropeptides . . . . .	93
Kinins . . . . .	93
Nitric oxide . . . . .	95
Reactive oxygen species . . . . .	98
Amines . . . . .	99
Summary . . . . .	101
Selected readings . . . . .	101
References . . . . .	101
<b>A.7 Immune response in human pathology: infections caused by bacteria, viruses, fungi, and parasites</b>	
Infections . . . . .	105
Natural resistance . . . . .	105

Specific resistance . . . . .	107
Defence against bacteria, viruses, fungi, and parasites . . . . .	109
Pathogenesis of shock . . . . .	110
Human immunodeficiency virus infection . . . . .	112
Vaccines and vaccination . . . . .	113
Infections in the new millennium . . . . .	114
Summary . . . . .	115
Acknowledgements . . . . .	115
Selected readings . . . . .	115
Recommended Websites . . . . .	115
<b>A.8 Immune response in human pathology: hypersensitivity and autoimmunity</b>	
Introduction . . . . .	117
Hypersensitivity . . . . .	117
Autoimmunity . . . . .	123
Conclusion . . . . .	125
Summary . . . . .	126
Selected readings . . . . .	126
Recommended website . . . . .	126
References . . . . .	126
<b>A.9 Cancer immunity</b>	
Introduction: cancer immunity from a historical perspective . . . . .	129
Key players in the immune responses against cancer . . . . .	130
Expression of targets for the immune System by cancer cells . . . . .	132
Immunotherapy of cancer . . . . .	136
Conclusions and future developments . . . . .	140
Summary . . . . .	141
Selected readings . . . . .	141
References . . . . .	142
<b>A.10 Neuroimmunoendocrinology</b>	
Historical background . . . . .	149
Regulation of the immune System by neuroendocrine hormones . . . . .	150
Neuroendocrine hormone release by immune System cells . . . . .	153
Functions of leukocyte-derived peptide hormones <i>in vivo</i> . . . . .	155
Summary and conclusions . . . . .	156
Acknowledgements . . . . .	157
Selected readings . . . . .	157
Recommended Websites . . . . .	157
References . . . . .	157
<b>B Immunodiagnosis</b>	
<b>B.1 Antibody detection</b>	
Introduction . . . . .	163
Basic principle of immunoassays . . . . .	163
Antibody structure . . . . .	164
Clinical relevance of antibody detection . . . . .	164

Antibody detection methods.....	165
Summary.....	170
Selected readings.....	170
References.....	170
<b>B.2    Immunoassays</b>	
Introduction.....	171
Basic principles of assay design.....	171
Components of immunoassays.....	173
Data presentation and curve plotting.....	175
Selected immunoassays.....	176
Assay Performance and validation.....	178
Summary.....	180
Selected readings.....	181
References.....	181
<b>B.3    Flow cytometry</b>	
Introduction.....	183
Mechanistic principles.....	183
Classification/types of assay.....	185
Components/construction of assays.....	187
Examples and their application.....	192
Summary.....	195
Selected readings.....	195
References.....	195
<b>B.4    Gene arrays</b>	
Introduction.....	197
Principle of the technology.....	197
Production of microarrays.....	201
Application of microarrays.....	203
Array data: acquisition, analysis and mining.....	205
Examples of microarray experiments.....	207
Summary.....	210
Selected readings.....	211
Recommended Websites.....	211
References.....	211
<b>B.5    Proteomics and applications within the drug development pipeline</b>	
Introduction.....	213
Traditional proteomics.....	213
Array-based proteomics.....	222
Summary.....	225
Selected readings.....	226
Recommended Websites.....	226
References.....	226

## C Immunotherapeutics

### C.1 Vaccines

Introduction . . . . .	231
Historical background . . . . .	231
Current vaccine categories . . . . .	232
Pharmacological effects of vaccination . . . . .	237
New developments . . . . .	239
Summary . . . . .	243
Selected readings . . . . .	244
Recommended Websites . . . . .	244
References . . . . .	244

### C.2 Sera and immunoglobulins

Humoral immunity . . . . .	247
Antibody structure . . . . .	247
Effector functions of human Ig . . . . .	249
The catabolism of Ig . . . . .	254
Ig preparations for medical use . . . . .	254
Indications . . . . .	256
Dosage and administration . . . . .	258
Side-effects of Ig therapy . . . . .	258
Monoclonal Ab (mAb) . . . . .	260
Summary . . . . .	262
Selected readings . . . . .	262
Recommended Websites . . . . .	263
References . . . . .	263

### C.3 Anti-allergic drugs

Introduction . . . . .	265
Disodium cromoglycate and nedocromil sodium (chromones) . . . . .	265
Histamine receptor antagonists . . . . .	270
Anti-IgE . . . . .	275
Summary . . . . .	277
Selected readings . . . . .	277
References . . . . .	278

### C.4 Drugs for the treatment of asthma and COPD

Introduction . . . . .	281
Bronchodilators . . . . .	281
Controller drugs . . . . .	300
Mediator antagonists . . . . .	309
Steroid-sparing therapies . . . . .	312
New drugs for asthma and COPD . . . . .	314
Other drugs . . . . .	328
Summary . . . . .	329
Selected readings . . . . .	330
Recommended Websites . . . . .	330
References . . . . .	330

<b>C.5</b>	<b>Immunostimulants in cancer therapy</b>	345
Introduction	345	
Recombinant proteins	345	
Natural and synthetic BRMs	357	
Combination immunotherapy and cellular therapy	363	
Conclusion	365	
Summary	366	
Selected readings	367	
Recommended Websites	367	
References	368	
<b>C.6</b>	<b>Anti-infective activity of immunomodulators</b>	377
Introduction	377	
Cytokine immunomodulators	378	
Interferons and combinations	379	
Colony-stimulating factors	381	
Emerging cytokine therapies	381	
Synthetic immunomodulators	383	
Emerging therapies with synthetic immunomodulators	384	
Microbial immunomodulators	386	
Summary	388	
Recommended Websites	388	
References	389	
<b>C.7</b>	<b>Mild plant and dietary immunomodulators</b>	391
Introduction	391	
Plant immunostimulants	391	
Zinc	394	
Dietary antioxidants	396	
Phenolic compounds as immunomodulators	400	
Emerging therapies and summary	403	
Selected readings	403	
Recommended Websites	403	
References	403	
<b>C.8</b>	<b>Influence of antibacterial drugs on the immune System</b>	407
Introduction	407	
Antibacterial agents (ABA) and the immune System	407	
Class-specific immunomodulatory effects	409	
Non-antibacterial effects of antibacterial agents. Therapeutic implications	426	
Conclusions	430	
Summary	430	
Selected readings	432	
Recommended Website	433	
References	433	
<b>C.9</b>	<b>Immunosuppressives in transplant rejection</b>	441
Introduction	441	
Calcineurin inhibitors	446	

Inhibitors of growth factor modulation. . . . .	450
Cytotoxic drugs. . . . .	451
Other immunosuppressive drugs. . . . .	454
Biologics. . . . .	455
New approaches and perspectives. . . . .	457
Summary. . . . .	460
Selected readings. . . . .	461
References. . . . .	461
<b>C.10 Cytotoxic drugs</b>	
Background. . . . .	465
Azathioprine. . . . .	465
Cyclophosphamide. . . . .	467
Fludarabine. . . . .	469
Methotrexate. . . . .	471
Mycophenolic acid. . . . .	474
Conclusions. . . . .	477
Summary. . . . .	477
Selected readings. . . . .	479
References. . . . .	479
<b>C.11 Corticosteroids</b>	
Introduction. . . . .	483
Chemical structures. . . . .	485
Modes of action. . . . .	485
Pharmacological effects. . . . .	487
Pharmacokinetics. . . . .	490
Clinical indications. . . . .	490
Side-effects. . . . .	492
Summary. . . . .	494
Selected readings. . . . .	494
Recommended Websites. . . . .	494
References. . . . .	494
<b>C.12 Non-steroidal anti-inflammatory drugs</b>	
Introduction. . . . .	499
Mode of action of non-steroid anti-inflammatory drugs. . . . .	499
Cyto-oxygenase-1 and cyclo-oxygenase-2. . . . .	500
Structural basis for COX-2 selectivity. . . . .	503
Additional uses for selective COX-2 inhibitors. . . . .	504
COX-2 inhibitors and cancers. . . . .	504
Premature labour. . . . .	505
Alzheimer's disease. . . . .	506
Other cyclo-oxygenases. . . . .	506
Summary. . . . .	506
Selected readings. . . . .	507
References. . . . .	508

<b>C 13</b>	<b>Disease-modifying anti-rheumatic drugs</b>	
Introduction.	.....	511
Pathophysiology of rheumatoid arthritis.	.....	511
Corticosteroids.	.....	512
Disease-modifying anti-rheumatic drugs (DMARD).	.....	514
Methotrexate.	.....	514
Antimalarials (chloroquine and hydroxychloroquine).	.....	520
Azathioprine.	.....	521
Cyclosporin.	.....	523
Gold complexes.	.....	525
Leflunomide.	.....	527
Penicillamine.	.....	530
Sulfasalazine.	.....	532
Tetracyclines (minocycline).	.....	533
Biological anti-rheumatic therapy.	.....	535
Combination DMARD therapies.	.....	536
Summary.	.....	537
Selected readings.	.....	539
References.	.....	540
<b>C.14</b>	<b>Perspectives of immunotherapy in the management of asthma and other allergic conditions</b>	
Introduction.	.....	545
General aspects of immunotherapy in allergy and asthma.	.....	545
Non-specific immunomodulatory therapies.	.....	546
Specific mediator antagonists.	.....	546
Anti-cytokine therapy.	.....	547
Cytokine therapy.	.....	547
Specific immunotherapy.	.....	548
Mechanisms of immunotherapy.	.....	548
SIT for asthma.	.....	549
Comparison of SIT with other types of treatment for asthma.	.....	549
Effects on natural history of allergic disease.	.....	549
Future directions.	.....	550
Conclusions.	.....	551
Summary.	.....	552
Selected readings.	.....	552
References.	.....	552
<b>D</b>	<b>Immunotoxicology</b>	
<b>D.1</b>	<b>Immunotoxicology</b>	
Introduction.	.....	559
Mechanisms of immunotoxicity by pharmaceuticals.	.....	560
Procedures for preclinical testing of direct immunotoxicity.	.....	570
Procedures for preclinical testing of sensitizing capacity.	.....	574
Procedures for immunotoxicity testing in humans.	.....	577
Immunotoxicity regulations.	.....	579
Conclusions.	.....	584
Summary.	.....	585
Selected readings.	.....	585
References.	.....	585

## Appendices

Appendix C.1.	593
Appendix C.3.	598
Appendix C.5.	602
Appendix C.6.	605
Appendix C.7.	606
Appendix C.8.	610
Appendix C.12/1.	611
Appendix <b>C.12/2</b> .	618
Appendix C.13.	623
Appendix D.1.	625
Glossary.	627
List of contributors.	645
Index.	651